Pharmacotherapy Review: Angiotensin Receptor Antagonists
The Journal of Clinical Hypertension, 2005 Angiotensin receptor blockers are one of several drug classes that act by interfering with activity of the renin‐angiotensin axis. Drugs in this class are as effective as angiotensin‐converting enzyme inhibitors in the reduction of blood pressure in hypertensive patients.
D. Sica
openaire +4 more sources
The impact of new tetralogy drugs on ventricular remodeling in heart failure patients: a systematic review and network meta-analysis [PDF]
BMC Cardiovascular DisordersBackground Heart failure, particularly heart failure with reduced ejection fraction (HFrEF), represents a major global health challenge due to its high prevalence, rapid progression, and substantial mortality rates.
Xi-Wen Wang +9 more
doaj +2 more sources
Spectrofluorimetric method for determination of some angiotensin II receptor antagonists
Journal of Pharmaceutical Analysis, 2012 A simple, rapid, accurate and highly sensitive spectrofluorimetric method has been developed for determination of some angiotensin II receptor antagonists (AIIRA's), namely Losartan potassium (Los-K), Irbesartan (Irb), Valsartan (Val) and Candesartan ...
Salwa R. El-Shaboury +3 more
doaj +2 more sources
Resistant Hypertension: Integration of Novel Agents and Interventional Approaches in Clinical Practice [PDF]
Reviews in Cardiovascular MedicineResistant hypertension (RH) is a high-risk phenotype characterized by blood pressure readings ≥130/80 mmHg despite maximally tolerated therapy with three antihypertensive agents, including a diuretic, or controlled blood pressure requiring four or more ...
Jose Arriola-Montenegro +12 more
doaj +2 more sources
Comparative Mortality in Heart Failure on Guideline‐Directed Medical Therapy Versus Malignant Cancer: A Report From a Global Federated Research Network [PDF]
Journal of the American Heart Association: Cardiovascular and Cerebrovascular DiseaseBackground Guideline‐directed medical therapy (GDMT), including angiotensin receptor‐neprilysin inhibitor, angiotensin‐converting enzyme inhibitors, beta blockers, mineralocorticoid receptor antagonists, and sodium‐glucose cotransporter‐2 inhibitors, has
Luca Monzo +6 more
doaj +2 more sources
Biomedical Papers, 2022 Aims. Sub-analysis of a retrospective nation-wide observational analysis of heart failure (HF) epidemiology reported to the Czech National Registry of Reimbursed Health Services between 2012 and 2018 aimed at angiotensin-converting enzyme inhibitors ...
Renata Aiglova +10 more
doaj +1 more source
Dynamics of endothelial dysfunction, nephropathic and dyslipidemic disorders in patients with insufficient glycemic compensation of type 2 diabetes mellitus during 1 year of application of angiotensin II receptor antagonists for hypertension correction [PDF]
Medičnì Perspektivi, 2014 The purpose of this study was to determine the dynamics of endothelial dysfunction, nephropathic and dyslipidemic disorders in patients with an insufficient compensation of type 2 diabetes mellitus and hypertension in the correction of blood pressure ...
Pertseva N.O.
doaj +3 more sources
Difficult choice: angiotensin receptor antagonists
Российский кардиологический журнал, 2013 The paper is focussed on the therapeutic choice of angiotensin receptor antagonists (ARA). The author presents the data on the comparison between different sartans and their benefits which are not explained by the blood pressure reduction.
E. O. Taratukhin
doaj +1 more source
Pharmacology and Therapeutics, 2016 We have reviewed the effects of angiotensin II type 1 receptor antagonists (ARBs) in various animal models of hypertension, atherosclerosis, cardiac function, hypertrophy and fibrosis, glucose and lipid metabolism, and renal function and morphology ...
M. Michel, H. Brunner, C. Foster, Y. Huo
semanticscholar +1 more source